FDA approves new treatment to slow progression of early Alzheimer’s

The FDA approved a new Alzheimer’s treatment called donanemab on Tuesday. It is designed to help patients in the early stages of the disease. CBS News chief medical correspondent Dr. Jon LaPook explains what to know. Source